Document is current
Any future updates will be listed below
-
Authors
Jensen, Rasmus Tanderup
Thuesen, Anne Cathrine Baun
Huang, Yun
Stinson, Sara Elizabeth
Juel, Helene Bæk
Madsbad, Sten
Bendtsen, Flemming
Hansen, Torben
Pedersen, Julie Steen
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden, Denmark (NNF17OC0028328, NNF15OC0016692)
BRIDGE – Translational Excellence Programme at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation (NNF20SA0064340)
Novo Nordisk Foundation Copenhagen Bioscience PhD (NNF18CC0033668)
The European Union's Horizon 2020 Research and Innovation Program (668031)
Copenhagen University
- License Information
-
More Information
Article History
Received: 23 September 2024
Revised: 30 November 2024
Accepted: 9 December 2024
First Online: 27 May 2025
Declarations
:
: TH: Have stocks in Novo Nordisk A/S and have received grants from Novo Nordisk A/S for other projects. SM; Advisory boards: AstraZeneca; Boehringer Ingelheim; Intarcia Therapeutics; Novo Nordisk; Sanofi, Abbott Lab, Bayer, Amgen. Lecture fees: AstraZeneca; Novo Nordisk, MSD. Research Grant Recipient: Novo Nordisk; Novo Nordisk foundation, Boehringer Ingelheim. Support for attending meetings and/or travel: Novo Nordisk, Boehringer-Ingelheim, Bayer No other authors have any conflict of interest.
